The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

The European Medicines Agency's Committee for Medicinal Products for Human Use has also given a positive opinion for InflaRx's drug GOHIBIC, which demonstrated a 23.9% relative reduction in 28-day ...

has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute ...

The European Medicines Agency's Committee for Medicinal Products for Human Use has also given a positive opinion for InflaRx's drug GOHIBIC, which demonstrated a 23.9% relative reduction in 28-day all ...